Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration

Annals of Hepatology

Volumn 14, Issue 1, 2015, Pages 75-82

  Zampino, Rosa ^a   Pisaturo, Maria A ^a   Cirillo, Grazia ^a   Marrone, Aldo ^a   Macera, Margherita ^a   Rinaldi, Luca ^a   Stanzione, Maria ^a   Durante Mangoni, Emanuele ^a   Gentile, Ivan ^b   Sagnelli, Evangelista ^a   Signoriello, Giuseppe ^a   del Giudice, Emanuele Miraglia ^a   Adinolfi, Luigi E ^a   Coppola, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Chronic hepatitis; HCC; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; GLUCOSE; LIPID; VIRUS RNA; ADIPONUTRIN, HUMAN; GLUCOSE BLOOD LEVEL; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE; VIRUS DNA;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CARBOHYDRATE INTOLERANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; BLOOD; CARCINOMA, HEPATOCELLULAR; COINFECTION; GENETICS; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TIME; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARCINOMA, HEPATOCELLULAR; COINFECTION; DNA, VIRAL; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIPASE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84918825536     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30803-8     Document Type: Article

References (50)

1. El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology 2012; 142: 1264-73.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5, Suppl. 1): S35-S50.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
4. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 64-70.
5. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49(5 Suppl.): S72-S84.
6. Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127: 1733-8.
7. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010; 28: 4587-93.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
9. Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res 2010; 40: 870-7.
10. Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, et al. The APOC3 T-455C and C- 482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011; 55: 1409-14.
11. Vigano M, Valenti L, Lampertico P, Facchetti F, Motta BM, D'Ambrosio R, Romagnoli S, et al. PNPLA3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013; 58: 1245-52.
12. Valenti L, Rumi MG, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, et al. Patatin-Like Phospholipase Domain-Containing 3 I148M Polymorphism, Steatosis, and Liver Damage in Chronic Hepatitis C. Hepatology 2011; 53: 791-9.
13. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013; 20: 517-23.
14. Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Dig Liver Dis 2013; 45: 619-24.
15. Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C, Santantonio T, et al. Influence of chronic HBV-HCV concurrent infection on liver histology. Infection 2004; 32: 144-8.
16. Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, Stanzione M, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther 2008; 13: 307-18.
17. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49: 1090-7.
18. Jamma S, Hussain G, Lau DT. Current Concepts of HBV/ HCV Coinfection: Coexistence, but Not Necessarily in Harmony. Curr Hepat Rep 2010; 9: 260-9.
19. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, Alberti A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-8.
20. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-54.
21. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 184-7.
22. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92: 607-12.
23. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and metaanalysis. Int J Cancer 2011;128:176-84.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
25. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008; 40: 603-17.
26. Prati D, Gasbarrini A, Mazzotta F, for AISF, SIMAST and SIMIT. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42: 81-91.
27. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon a-2a and a-2b in patients with genotype 1 chronic hepatitis C: a metaanalysis. BMC Infect Dis 2012; 12: 357.
28. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
29. Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Medical Virol 2011; 83: 1909-16.
30. Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44: 49-54.
31. Miraglia del Giudice E, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C, Savarese P, et al. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One 2011; 6: e27933.
32. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42(Suppl. 3): S206-14.
33. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, Abiru S, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
34. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009; 44(Suppl. 19): 82-8.
35. Na TY, Shin YK, Roh KJ, Kang SA, Hong I, Oh SJ, Seong JK, et al. Liver X receptor mediates hepatitis B virus X protein- induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009; 49: 1122-31.
36. Ha HL, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. World J Gastroenterol 2010; 16: 4932-7.
37. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, et al. Hepatitis B Virus X Protein Induces Hepatic Steatosis Via Transcriptional Activation of SREBP1 and PPARgamma. Gastroenterology 2007; 132: 1955-67.
38. Wu Q, Liu Q. Do hepatitis B virus and hepatitis C virus coinfections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression? Hepatology Research 2012; 42: 733-40.
39. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW Jr, Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997; 337: 1705-14.
40. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-31.
41. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
42. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-56.
43. Thursz M, Brown A. Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma? Gut 2011; 60: 1025-6.
44. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-9.
45. Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 329-46.
46. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
47. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28: 109-22.
48. Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, Overvad K, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013; 24: 2449-55.
49. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.
50. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001; 96: 2462-7.